Viatris (VTRS) AI Stock Analysis

Company Guidance

Viatris raised the midpoint of its 2026 guidance across all key metrics — at the midpoint the company now expects roughly 2% operational revenue growth, ~5% adjusted EBITDA growth and ~7% adjusted EPS growth versus 2025 — building on Q2 results of $3.8 billion revenue (+3.5% op), $1.2 billion adjusted EBITDA, $0.69 adjusted EPS and a 57.5% adjusted gross margin (Q2 free cash flow $329M, or $449M excluding transaction/restructuring costs and taxes). Management said full-year revenues are weighted to the second half (~51%), that adjusted EBITDA and EPS will be slightly lower in H2 while free cash flow is back‑end loaded, and that guidance already incorporates a $100–150M H2 revenue headwind from Nashik supply disruptions plus the expected Tyrvaya divestiture. Capital allocation metrics: ~$1.4B deployed year‑to‑date (including ~$550M returned to shareholders and ~$270M of buybacks), ~ $900M of maturing debt repaid, ~2.9x gross leverage (target range 2.8–3.2x), and approximately $1.6B of deployable capital remaining (including ~ $380M pretax Biocon proceeds). Segment-level 2026 expectations were provided: Greater China low double‑digit growth, developed markets roughly flat (North America slightly down), emerging markets low single‑digit growth and JANZ a low single‑digit decline.